ADORA3 and psoriasis: CF101, a selective A3AR full agonist that is currently under development for rheumatoid arthritis and psoriasis (Fishman and Cohen, 2016[6]), was well-tolerated in nonclinical studies and Phase I clinical trials with healthy subjects (van Troostenburg et al., 2004[26]).